Abeona Therapeutics Inc Debt / Equity
Cos'è Debt / Equity di Abeona Therapeutics Inc?
Debt / Equity di Abeona Therapeutics Inc è 3.32
Qual è la definizione di Debt / Equity?
Il rapporto debito è un rapporto finanziario che indica la proporzione relativa del patrimonio netto e del debito utilizzato per finanziare le attività di una società.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt / Equity di aziende nel Health Care settore su NASDAQ rispetto a Abeona Therapeutics Inc
Cosa fa Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Aziende con debt / equity simili a Abeona Therapeutics Inc
- Core-Mark Hldg Co Inc ha Debt / Equity di 3.31
- Haitong International Securities ha Debt / Equity di 3.31
- Wall ha Debt / Equity di 3.31
- Southern ha Debt / Equity di 3.31
- Puma Biotechnology Inc ha Debt / Equity di 3.31
- Haitong Securities Co ha Debt / Equity di 3.32
- Abeona Therapeutics Inc ha Debt / Equity di 3.32
- Grammer AG ha Debt / Equity di 3.32
- Butn ha Debt / Equity di 3.32
- GAM AG ha Debt / Equity di 3.32
- HeraMED ha Debt / Equity di 3.32
- Great Ajax Corp ha Debt / Equity di 3.32
- HENSOLDT GmbH ha Debt / Equity di 3.32